Combining Gut-Brain Pathway Drugs Offers Strong Rationale for Obesity Treatment.

Obesity is a complex chronic disease driven by dysregulation of the gut-brain axis, which controls appetite and metabolism. Current monotherapies often achieve modest weight loss and face limitations due to compensatory mechanisms, leaving a significant unmet need. This review explores the rationale for combination pharmacotherapy by targeting multiple, distinct gut-brain pathways to achieve more profound and sustained weight reduction.